Lenvatinib mesylate in Unresectable Hepatocellular Carcinoma: NCT07408804 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Not Applicable
Clinical phase
Recruiting
Recruitment status
not reported
Planned enrollment
2026-09-30
Primary-completion proxy
Executive view
NCT07408804 evaluates Lenvatinib mesylate in Unresectable Hepatocellular Carcinoma. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Bangladesh. The first listed primary endpoint is To compare the objective response rate between a combination of Transarterial Chemoembolization and Lenvatinib therapy versus Lenvatinib monotherapy in patients with unresectable Hepatocellular carcinoma, assessed over at baseline and after 3 months of initiation of treatment.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07408804 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Unresectable Hepatocellular Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Lenvatinib mesylate, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07408804 | Lenvatinib mesylate | Not Applicable / Recruiting | Sponsor not reported | Bangladesh | To compare the objective response rate between a combination of Transarterial Chemoembolization and Lenvatinib therapy… at baseline and after 3 months of initiation of treatment | 2026-09-30 |
| NCT07558200 | TEV-56278 | Phase 1 / Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | China | Incidence and severity of dose-limiting toxicities (DLTs) in Phase Ia First 2 cycles after first dose (each cycle = 14 days; approximately… | 2030-04-23 |
| NCT07557251 | Sintilimab | Phase 1 / Recruiting | Cancer Hospital Chinese Academy of Medical Sciences | China | Incidence and type of dose-limiting toxicities (DLTs) Up to 30 days post last dose | 2028-12-01 |
| NCT07553767 | Tenofovir Alafenamide Fumarate | Early Phase 1 / Not yet recruiting | Ningbo No. 2 Hospital | China | Concentration of Hepatitis B Surface Antigen (Hepatitis B Surface Antigen, HBsAg) Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216… | 2034-12-31 |
| NCT07551778 | Cetuximab | Phase 1/2 / Not yet recruiting | BOE Technology Group Co., Ltd. | Geography not reported | Dose-Limiting Toxicity (DLT) During the first treatment cycle (21 days for Cohorts 1&3, 14 days fo… | 2028-04-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07408804 is a Not Applicable, recruiting study with not reported planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “To compare the objective response rate between a combination of Transarterial Chemoembolization and Lenvatinib therapy versus Lenvatinib monotherapy in patients with unresectable Hepatocellular carcinoma” over “at baseline and after 3 months of initiation of treatment.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Lenvatinib mesylate as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Unresectable Hepatocellular Carcinoma. These records do not establish direct evidence for NCT07408804 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Lenvatinib mesylate is indexed as Small molecule drug with FGFR1 x FGFR2 x FGFR3 x FGFR4 x PDGFRα x RET x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit biology and a global stage of Approved. The asset profile lists Eisai Co., Ltd. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Lenvatinib mesylate is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07408804
Protocol source: https://clinicaltrials.gov/study/NCT07408804
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
Lenvatinib mesylate in Unresectable Hepatocellular Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To compare the objective response rate between a combination of Transarterial Chemoembolization and Lenvatinib therapy versus Lenvatinib monotherapy in patients with unresectable Hepatocellular carcinoma and 2026-09-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
